Dr. Jonathan A. Coleman

From the heart of Memorial Sloan Kettering Cancer Center, Dr. Jonathan A. Coleman convenes a distinguished multidisciplinary team—including urologic surgeons, medical oncologists, radiation oncologists, pathologists and supportive care specialists—to ensure every treatment recommendation reflects both tumor biology and patient priorities. His position as Attending Urologic Surgeon and David H. Koch Chair for Urologic Oncology underscores his dedication to collaborative, patient-focused care. Weekly tumor boards bring together advanced diagnostic imaging and molecular pathology data with clinical insights, guiding personalized pathways that blend organ preservation strategies, systemic therapies and supportive services. He co-chairs institutional committees that standardize evidence-based protocols for renal and prostate malignancies and represents MSKCC in national guideline consortia. Dedicated patient navigators streamline appointment coordination, psychosocial support and survivorship planning, reducing delays and enhancing treatment adherence. By embedding integrated workflows and functional recovery metrics into routine practice, he fosters a seamless care continuum that bolsters patient confidence in each step of their treatment journey.

 

In his translational research laboratory, Dr. Coleman applies cutting-edge sequencing technologies and three-dimensional organoid models to unravel tumor–microenvironment interactions and resistance pathways in urologic malignancies. Leading initiatives on androgen-receptor signaling and HER2 genomic alterations, he has shaped targeted therapy exploration in upper tract urothelial carcinoma. His flagship trial combining WST-11 vascular-targeted photodynamic therapy with gemcitabine exemplifies his bench-to-bedside approach, informing both patient selection and therapeutic protocols. He guides adaptive trial designs and basket studies that broaden access to novel agents, while steering a seminar series that bridges clinical investigators, basic scientists and industry collaborators. Mentorship programs under his leadership cultivate expertise in bioinformatics pipelines and functional assay development among research fellows. Collaborations with pharmaceutical partners have accelerated target validation and early-phase planning for promising agents. Integrating circulating tumor DNA monitoring into protocols allows dynamic treatment adjustments, ensuring that every clinical encounter harnesses the latest molecular insights. Patients benefit from trial options informed by robust genomic profiling and functional assays, reinforcing trust in therapies tailored to their tumor’s unique biology.

 

Building on his academic role at Weill Cornell Medical College, Dr. Coleman champions education and outreach through national symposia, patient workshops and multimedia resources that demystify surgical options, disease biology and survivorship considerations. He has authored accessible booklets on rehabilitation, genomic testing interpretation and side-effect management, ensuring patients and caregivers receive clear, actionable information. His curriculum designs for medical students, residents and fellows integrate simulation training, interdisciplinary case studies and molecular diagnostics to deepen clinical acumen in minimally invasive techniques. Extending beyond the tertiary care setting, he implements telemedicine consultations and mobile screening events in underserved communities, partnering with advocacy groups for virtual seminars on early detection and quality-of-life planning. His online clinical trial matching portal streamlines eligibility navigation and enrollment tracking, empowering patients to engage with research opportunities. Bilingual educational materials and interdepartmental grand rounds further expand reach across diverse populations. Through these initiatives, he ensures patients and providers alike stay informed of evolving standards, fostering an environment of empowerment and clarity at every care stage.